128 related articles for article (PubMed ID: 25546612)
1. Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer.
Li X; Sun L; Hou J; Gui M; Ying J; Zhao H; Lv N; Meng S
Int J Cancer; 2015 Aug; 137(3):512-24. PubMed ID: 25546612
[TBL] [Abstract][Full Text] [Related]
2. Blockage of conformational changes of heat shock protein gp96 on cell membrane by a α-helix peptide inhibits HER2 dimerization and signaling in breast cancer.
Li X; Wang B; Liu W; Gui M; Peng Z; Meng S
PLoS One; 2015; 10(4):e0124647. PubMed ID: 25898135
[TBL] [Abstract][Full Text] [Related]
3. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo.
Kawamoto M; Horibe T; Kohno M; Kawakami K
Mol Cancer Ther; 2013 Apr; 12(4):384-93. PubMed ID: 23358664
[TBL] [Abstract][Full Text] [Related]
6. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HER2-Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2-Glycan-Imprinted Nanoparticles.
Dong Y; Li W; Gu Z; Xing R; Ma Y; Zhang Q; Liu Z
Angew Chem Int Ed Engl; 2019 Jul; 58(31):10621-10625. PubMed ID: 31166063
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
9. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
[TBL] [Abstract][Full Text] [Related]
10. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms.
Arnal-Estapé A; Tarragona M; Morales M; Guiu M; Nadal C; Massagué J; Gomis RR
Cancer Res; 2010 Dec; 70(23):9927-36. PubMed ID: 21098707
[TBL] [Abstract][Full Text] [Related]
11. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
[TBL] [Abstract][Full Text] [Related]
12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
13. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474).
Mason JK; Fu M; Chen J; Thompson LU
J Nutr Biochem; 2015 Jan; 26(1):16-23. PubMed ID: 25441844
[TBL] [Abstract][Full Text] [Related]
14. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.
Menendez JA; Schroeder B; Peirce SK; Vellon L; Papadimitropoulou A; Espinoza I; Lupu R
J Natl Cancer Inst; 2015 Jun; 107(6):djv090. PubMed ID: 25888715
[TBL] [Abstract][Full Text] [Related]
15. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
[TBL] [Abstract][Full Text] [Related]
16. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
Pickl M; Ries CH
Oncogene; 2009 Jan; 28(3):461-8. PubMed ID: 18978815
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
[TBL] [Abstract][Full Text] [Related]
20. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
